A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia. SEO and diligence focus: Ipilimumab, Nivolumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.